"FLAMES: A novel burning entity in MOG IgG associated disease". Jain K, Cherian A, K P D, P R, Thomas B, J N.Unfavorable outcome in highly relapsing MOGAD encephalitis. Buciuc M, Sechi E, Flanagan EP, Lopez-Chiriboga AS.Clinical presentation and prognosis in MOG-antibody disease: a UK study. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J.The long-term outcome of MOGAD: An observational national cohort study of 61 patients. Deschamps R, Pique J, Ayrignac X, Collongues N, Audoin B, Zéphir H, Ciron J, Cohen M, Aboab J, Mathey G, Derache N, Laplaud D, Thouvenot E, Bourre B, Ruet A, Durand-Dubief F, Touitou V, Vignal-Clermont C, Papeix C, Gout O, Marignier R, Maillart E NOMADMUS study group.Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ.Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP).Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Chen JJ, Huda S, Hacohen Y, Levy M, Lotan I, Wilf-Yarkoni A, Stiebel-Kalish H, Hellmann MA, Sotirchos ES, Henderson AD, Pittock SJ, Bhatti MT, Eggenberger ER, Di Nome M, Kim HJ, Kim SH, Saiz A, Paul F, Dale RC, Ramanathan S, Palace J, Camera V, Leite MI, Lam BL, Bennett JL, Mariotto S, Hodge D, Audoin B, Maillart E, Deschamps R, Pique J, Flanagan EP, Marignier R.MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, Paul F, Levy M.Clinical decision making in MOG antibody-associated disease. Frequency of MOG-IgG in cerebrospinal fluid versus serum. Pace S, Orrell M, Woodhall M, Palace J, Leite MI, Irani SR, Waters P, Handel AE.Part 1: Results from 163 lumbar punctures in 100 adult patients. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hümmert MW, Ringelstein M, Rommer PS, Ayzenberg I, Ruprecht K, Klotz L, Asgari N, Zrzavy T, Höftberger R, Tobia R, Buttmann M, Fechner K, Schanda K, Weber M, Asseyer S, Haas J, Lechner C, Kleiter I, Aktas O, Trebst C, Rostasy K, Reindl M, Kümpfel T, Paul F, Wildemann B in cooperation with the Neuromyelitis Optica Study Group (NEMOS).Myelin-oligodendrocyte glycoprotein antibody-associated disease. Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Alexopoulos H, Amato MP, Asgari N, Banwell B, Bennett J, Brilot F, Capobianco M, Chitnis T, Ciccarelli O, Deiva K, De Sèze J, Fujihara K, Jacob A, Kim HJ, Kleiter I, Lassmann H, Leite MI, Linington C, Meinl E, Palace J, Paul F, Petzold A, Pittock S, Reindl M, Sato DK, Selmaj K, Siva A, Stankoff B, Tintore M, Traboulsee A, Waters P, Waubant E, Weinshenker B, Derfuss T, Vukusic S, Hemmer B.Differential efficacy of mycophenolate mofetil in adults with relapsing myelin oligodendrocyte glycoprotein antibody-associated disorders. Wang M, Zeng P, Du C, Xue H, Cui Z, Zhang H, Jia D, Zhang C.Neurological update: MOG antibody disease. Wynford-Thomas R, Jacob A, Tomassini V.MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany. Liu J, Mori M, Zimmermann H, Brandt A, Havla J, Tanaka S, Sugimoto K, Oji S, Uzawa A, Asseyer S, Cooper G, Jarius S, Bellmann-Strobl J, Ruprecht K, Siebert N, Masuda H, Uchida T, Ohtani R, Nomura K, Meinl E, Kuempfel T, Paul F, Kuwabara S.
0 kommentar(er)
